Xenetic Biosciences, Inc. (XBIO) Form 8-K — Aug 7, 2026
Xenetic Biosciences (NASDAQ: XBIO) reported second quarter 2026 results, with royalty revenue up approximately 12% year-over-year to roughly $0.7 million, driven primarily by its sublicense agreement with Takeda Pharmaceuticals. Net loss widened to approximately $0.9 million from about $0.7 million in the prior-year quarter. G&A expenses jumped approximately 64% to $1.1 million, mainly from legal costs tied to the board's ongoing strategic review process, while R&D spending fell approximately 16% to $0.6 million on lower manufacturing development and consulting costs. The company ended the quarter with roughly $6.5 million in cash, down from about $7.9 million at year-end 2025.
Key figures
- Revenue Yoy
- approximately 12%
- Cash Position
- 6500000
- Cash Dec31 2025
- approximately $7.9 million
- Net Loss Q2 2025
- approximately $0.7 million
- Ga Expenses Q2 2026
- approximately $1.1 million (up ~64% YoY)
- Rd Expenses Q2 2026
- approximately $0.6 million (down ~16% YoY)
- Royalty Revenue H1 2026
- approximately $1.5 million
- Royalty Revenue Q2 2025
- approximately $0.6 million
- Royalty Revenue Q2 2026
- approximately $0.7 million
Price after filing
Close on the filing date to close N calendar days later (from $2.96). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.